Elevated PSA
7
2
4
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
14.3%
1 terminated out of 7 trials
66.7%
-19.8% vs benchmark
14%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Upright MRI for Prostate Cancer Screening
Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA
PSMA PET Combined With MRI for the Detection of PCa
Marker Driven Selection of Patients for Prostate Biopsy and Management
A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches
Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer
Functional and Morphologic MRI in the Detection of Prostate Cancer in Patients With Prior Negative Biopsy